PARP1 and ovarian cancer: In relapsed platinum-sensitive disease, BRCA1/2-mutant ovarian cancer, the olaparib durvalumab combination demonstrated an ORR of 63%, which is also compatible with the PARP inhibitor monotherapy activity in this setting [80].